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Abstract 
Background: The blood brain barrier (BBB) controls the brain microenvironment and limits penetration of the central 
nervous system (CNS) by chemicals, thus creating an obstacle to many medical imaging and treatment procedures. 
Research efforts to identify viable routes of BBB penetration have focused on structures such as micelles, polymeric 
nanoparticles and liposomes as drug carriers, however, many of them failed to provide unequivocal proof of BBB pen-
etration. Here we proved that gold nanoparticles (AuNPs) penetrate the BBB in rats to reach brain regions.
Results: Injection of AuNPs to the abdominal cavity of rats resulted in levels of gold found in blood, urine, brain 
regions and body organs. After perfusion the concentration of gold in brain regions diminished dramatically indi-
cating that most of the gold was in venous blood and not in the brain tissues. Injection of Na, K or Ca ion channel 
blockers reduced BBB penetration by half. A biological half-life of 12.9 ± 4.9 h was found for the gold nanoparticles. 
Possible mechanisms for the transport of AuNPs through the BBB are discussed.
Conclusions: BBB penetration by AuNPs is spontaneous without the application of an external field. A major amount 
of gold resides in blood vessels therefore perfusion required. Ion channel blockers can be used to control the trans-
port of AuNPs.
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Background
Rigorous control of the brain microenvironment, essen-
tial to support neural signaling within the central nerv-
ous system (CNS), is provided by the blood-brain barrier 
(BBB). Present in all organisms with a developed CNS 
[1–3] the BBB not only prevents harmful agents from 
penetrating the CNS, it also blocks the delivery of drugs 
and therapeutics to the CNS. As such, the BBB has been 
an obstacle to the development of new drugs for the CNS. 
Indeed, most CNS drug candidates, essentially 100 % of 
large-molecule drugs and about 98 % of small-molecule 
drugs, cannot autonomously penetrate the BBB, and 
therefore, they also cannot access the brain [4].
Of the drugs that are able to cross the BBB, most do so 
via transmembrane diffusion, a mechanism that depends 
on the drug’s structural or chemical link to the cell mem-
brane, and on integration or permeability through it. 
These phenomena, are mostly observed for low molecu-
lar weight and high lipid solubility are favored. Other 
molecular characteristics that can affect the partition-
ing of a drug molecule between the blood and the brain 
include molecular charge, tertiary structure and degree 
of protein binding [4]. In addition to transmembrane dif-
fusion, some macromolecules, such as transferrin, are 
able to cross the BBB via a receptor-mediated process [5].
In the search for a viable approach to deliver thera-
peutics across the BBB, a number of prerequisites must 
be fulfilled. The process should be controllable and safe, 
with no negative effect on BBB integrity, and it should 
be biocompatible and selective [4–8]. Furthermore, as a 
method of target-specific drug delivery, it should deliver 
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the drug to the site of intended action in the brain, where 
the drug load should be adequate such that therapeutic 
concentrations are obtained and maintained for sufficient 
time at the site targeted in the brain.
Numerous approaches of improving drug delivery to 
the brain have been reported [4–9]. Since BBB impen-
etrability is due to the presence of tight junctions (TJ) 
that prevent the passage of drug molecules, an obvious 
solution is to open the BBB in a controlled and reversible 
manner by disrupting its tight junctions, thereby ena-
bling substances to infiltrate to the brain. To breach the 
tight junctions, various mechanisms such as the admin-
istration of osmotic solutions [10] or the application of a 
physical stimulus such as ultrasound [11] have been used. 
Different, noninvasive routes entailed the development 
of nanosystems such as liposomes, polymeric nanopar-
ticles, solid lipid nanoparticles, polymeric micelles, and 
dendrimers that are able to deliver drugs to the brain. 
Administered intravenously, such colloidal drug carri-
ers can leave the bloodstream and enter organs that pos-
sess porous endothelial capillaries. Despite the potential 
of these nanosystems, however, their insufficient BBB 
permeability confers on them only a limited capacity to 
transport therapeutics to the brain [5, 6, 9].
Perhaps the carrier method with the most promise 
entails gold nanoparticles (AuNPs), whose relevance 
extends beyond the transport of drugs to include other 
medicinal applications, such as imaging [12–14], radio-
therapy of tumors [15, 16] and photo-thermal therapy 
[13]. In addition, AuNPs are also known for their ease of 
synthesis [17–19], simple functionalization procedures 
using therapeutic molecules [18, 19] and their good bio-
compatibility [20]. Taken together with their wide ther-
apeutic applicability, the user-friendly, biocompatible 
nature of AuNPs makes them ideal candidates for BBB 
penetration.
The aims of the present study were to study the pen-
etration of the BBB by gold nanoparticles and examine 
the effect of ion channel blockers on the transport of the 
AuNPs, as well as study the biokinetics of the distribution 
of the gold throughout several body organs and brain 
regions.
A proof for nanoparticle penetration through the BBB 
has been demonstrated by radiotherapy of brain tumors 
in mice [15, 16]. The present study provides unequivocal 
proof of spontaneous penetration of the BBB by AuNPs 
in the absence of an applied external field. Similar proce-
dure to the one described here was used in Ref. [14].
Results
We began our investigation by comparing the BBB pen-
etrability of six different types of AuNPs distinguished 
by route of synthesis (see methods section). Five of the 
synthesized AuNPs were hydrophilic, and the sixth was 
hydrophobic due to a layer of perfluoro decanethiol 
(PFDT) adsorbed onto the particle surface. Whereas 
all the hydrophilic particles penetrated the BBB, the 
PFDT-functionalized particles did not. These results 
suggest that although the BBB is lipophilic in nature, 
hydrophilic AuNPs have higher probability to sponta-
neously penetrate the BBB. It should be noted that the 
AuNPs are covered by an organic layer that prevents 
them from agglomeration during their synthesis. When 
plant extracts were used as reducing agents, the detailed 
chemical nature of the organic layer is not fully identi-
fied, however, it contains many polar groups such as 
OH, NH and C=O (see Table  2 in Ref. [21]). The pre-
liminary experiments with the six AuNPs suggested that 
those synthesized using Pelargonium graveolens (Rose 
Geranium) extract crossed the BBB with the highest effi-
ciency, as discussed earlier [21] and in Additional file 1, 
hence, all the experiments reported below employed this 
type of AuNPs.
Our first goal was to provide proof that gold nanopar-
ticles indeed penetrate the BBB. The brain is surrounded 
by, and contains, a very large number of blood vessels. 
Because the gold levels measured in the brain tissue are 
expected to be dominated by the gold content of the 
venous blood, a perfusion procedure was performed to 
remove venous blood from the brain tissues. After AuNP 
injection, gold concentrations in the different regions 
of the brain were measured with and without perfusion 
(Table 1).
In another experiment, AuNPs were injected abdomi-
nally into a rat. After 24 h the animal was sacrificed fol-
lowing perfusion, and its brain was frozen and dissected 
into 25  μm thick slices. A slice that contained the hip-
pocampus and hypothalamus regions was selected for 
analysis via laser ablation inductively coupled plasma 
mass spectrometry (LA-ICP-MS). 2D images were con-
structed for the gold concentration distributions in 
the hypothalamus and in the hippocampus. The gold 
Table 1 Gold concentrations in different brain regions fol-
lowing AuNP injection with and without perfusion
Gold concentrations (μg/g/mg gold injected) measured in different brain 
regions following AuNP injection with and without perfusion. To allow 
comparison between the results of the different experiments, the data were 
normalized to the amount of gold injected in each experiment
a A single high concentration value defined as an outlier was omitted. If 
this value is included the gold concentration found in the hypothalamus is 
3.2 ± 5.2 μg/g/mg gold injected
Organ Perfusion (N = 4) No perfusion (N = 2)
Frontal cortex 0.63 ± 0.27 6.21 ± 4.69
Hippocampus 0.56 ± 0.39 3.19 ± 3.45
Hypothalamus 0.31 ± 0.16a 4.56 ± 5.12
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distribution in both brain regions was found to be practi-
cally uniform (see Additional file  2: Figure S2), suggest-
ing that there were no preferred or selective penetration 
regions in these regions of the brain.
Next, the bio-kinetic profile of AuNPs in the rat body 
was studied. The profiles were obtained by sacrificing rats 
at predefined times after the injection of gold particles 
(2, 6, 16, 24, 36 and 48  h). After the rat was sacrificed, 
gold concentrations were measured in the kidney, liver, 
spleen and in brain regions (hippocampus, hypothala-
mus, frontal cortex and cerebellum). In many cases we 
could only extract part of the organ, hence, the concen-
tration was determined as amount of Au in 1 gr of organ 
tissue. Two sets of experiments were performed, and for 
each, a freshly synthesized AuNP solution was prepared 
and used. In the first set of experiments the gold concen-
tration in the solution was 105 mg/L while in the second 
set it was 60  mg/L The results are presented in Fig.  1. 
It should be noted that each data point in Fig.  1 corre-
sponds to different rat.
To examine the importance of individual rat physi-
ology, we compared gold concentrations in the urine 
of a single rat at different time points with the values 
obtained for other rats at the same time points (second 
set of experiments). The comparison results are summa-
rized in Table 2.
The final step in the present study was to assess the 
route through which the AuNPs penetrate the BBB. There 
are several possible mechanisms for penetration of nano-
particles through cell membranes including diffusion, 
direct penetration, via energy independent pathways and 
endocytosis [22]. The characteristics of the AuNPs used 
in this study, as discussed in previous work [21], exclude 
diffusion as the dominant mechanisms. The importance 
of direct penetration and penetration through specific 
transport sites was examined by blocking ion channels 
using dofetilide [23] and phenytoin [24] as K+ and Na+ 
ion channel blockers, respectively, and verapamil as a 
Ca2+ ion channel blocker [25]. Three sets of experiments 
with three rats in each set were carried out (i.e. total of 
nine rats). In each set freshly synthesized AuNP solutions 
were used for injection to each one of the three animals 
in the set according to the usual procedure described in 
the methods section below. One hour after AuNPs injec-
tion, one rat of the set was injected in its abdominal cav-
ity with verapamil equal to 0.1 mg kg−1 rat body weight, 
a second rat was injected with a solution of dofetilide 
and phenytoin equal to 1 μg kg−1 and 8 mg kg−1 rat body 
weight, respectively. The third animal in each set served 
as control.
All the animals were sacrificed 3  h after the AuNPs 
injection. The concentrations of gold in three brain 
regions (frontal cortex, hippocampus and hypothalamus) 
were measured for each rat in the three sets examined. 
However, since the initial concentration of the AuNP 
solutions used for injection to each set had different Au 
concentration, the gold concentration measured in the 
various brain regions were normalized by the Au con-
centration in the solution used for the injection in each 
set. Some variations in gold concentration in the differ-
ent brain regions were observed for the rats in each set. 
Since our main interest was in the overall influence of 
ion-channel blockers on the BBB permeation, the nor-
malized gold concentration values, observed in the three 
brain regions in the three sets of experiments, were aver-
aged. The average and standard deviation values obtained 
are presented in Fig. 2. The results shown in Fig. 2 clearly 
show that in the rats that were injected with ion channel 
blockers half the concentration of gold is found to cross 
the BBB compared to the corresponding value found in 
the control group.
Discussion
With each heartbeat, arteries carry about 20–25 % of the 
total body blood to the brain. There are a large number 
of blood vessels surrounding the brain tissues and their 
structure is highly branched. Thus, the gold levels meas-
ured in the brain tissue are dominated by the gold con-
tent of the venous blood unless a perfusion procedure is 
carried out. The true level of gold in the brain tissues can 
be obtained after removal of venous blood to ensure that 
the measured gold level reflects the amount that pen-
etrated the BBB.
The data in Table 1 show that the gold concentrations 
in all brain regions were significantly lower with perfu-
sion than without it. The large post-perfusion reduction 
in gold concentration indicates that most of the gold 
measured without perfusion originated from the blood 
in the capillaries in the brain tissue and was not due to 
nanoparticle penetration of the BBB.
In a second set of experiments, cerebrospinal fluid 
(CSF) samples were collected after AuNPs injection and 
tested for the presence of gold. The average gold concen-
trations in CSF samples collected 6 h after injection was 
0.16 mg L−1. Since the CSF is contained within a closed 
system surrounding the brain, the presence of gold in the 
CSF provides further evidence that AuNPs indeed pen-
etrated the BBB.
Two sets of experiments were carried out in order to 
study the bio-kinetic behavior of the gold nanoparticles 
in the rat body. A comparison between the data obtained 
in the two experiments shows that the gold concentra-
tions differed consistently by a factor of approximately 
five. This was attributed to the difference in size distribu-
tion of the AuNPs (about 98 % of which had a mean size 
of 1.3 ±  0.3 nm) in both preparations. This assumption 
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is supported by the similarity in the profiles of the tem-
poral behavior of the changes in gold concentration in 
the two experiments where, at 6–16 h after injection, the 
gold concentrations in the different brain regions reached 
their maximum levels.
Figure 1a and 1b show that the gold concentrations in 
the different brain regions varied during the 48  h after 
AuNP injection. Similar data are presented in Fig. 1c and 
1d for the different organs examined. Note that technical 
difficulties in the first set of experiments prevented meas-
urements of gold concentration in the cerebellum after 
2 h. The picture that emerges from these results (Fig. 1a–
d) is of a rapid initial increase in gold concentration to a 
maximum level after 6–16  h, followed by a fast decline 
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Fig. 1 The biokinetic profiles of gold concentrations in different organs and regions of the brain as a function of the time after injection. Panels a, c 
and e correspond to the first set of experiments, while panels b, d and f correspond to the second set. a Variation of gold concentration in different 
brain regions in the first set of experiments. b Same as a for the second set of experiments. c Variation of gold concentration in internal organs in 
the first set of experiments. d Same as c for second set of experiments. e Variation of gold concentration in the blood in the first set of experiments. 
f Variation of gold concentration in the CSF in the second set of experiments
Page 5 of 9Sela et al. J Nanobiotechnol  (2015) 13:71 
until it levels out after about 24 h and slowly continues to 
decrease to a negligible level.
Considering the number and spacing of the data points, 
the maximum gold concentration cannot be determined 
more precisely. Even considering that each data point 
in Fig. 1 corresponds to a different animal that was sac-
rificed at that time the temporal profile indicates that 
individual differences in rat physiology had only a minor 
effect on the results. This conclusion was supported in 
complementary experiments designed to explore the 
urine kinetic profile of a single rat compared with the 
average values obtained for four other rats at the same 
time points (Table 2).
The gold concentration profiles in samples of blood 
(first set of experiments) and of CSF (second set of exper-
iments) are shown (Fig. 1e and 1f, respectively). In both 
cases maximum gold concentration was obtained 6  h 
after AuNP injection, which subsequently decreased rap-
idly in both fluids. Because the AuNP solution is injected 
into the abdominal cavity of the animals, it is clear that 
its concentrations in different organs and brain regions 
are highly correlated with the gold concentration in the 
blood, the AuNP transport media.
In general, all brain regions and organs examined, as 
well as the CSF, demonstrated similar time dependent 
profiles variation of gold concentrations characterized by 
rapid increase in gold concentration during the first 10 h 
after injection followed by a decrease in concentration to 
low levels 24–48  h after injection. These variations are 
attributed to the variable gold concentration in the blood, 
which is the source of AuNP supply for all body organs, 
including the brain regions. Based on these results, the 
biological half-life of the gold nanoparticles in the rats’ 
bodies was estimated as 12.9 ± 4.9 h.
Possible pathways of the particle penetration through 
the BBB were investigated in order to complete the 
characterization study. The ability of nanoparticles to 
penetrate cell membrane was demonstrated by several 
research groups [26–31]. These studies clearly showed 
that the ability of nanoparticles to penetrate into cells 
is highly dependent on the type of cell and the particle 
characteristics such as size, surface charge and surface 
chemical composition. For example, it was confirmed 
that cationic nanoparticle have a much larger tendency to 
cross cell membrane compared to anionic nanoparticles 
[26, 27]. Since the gold nanoparticles used in this study 
had hydrophilic coating and were negatively charged 
(−23.9 ± 2 mV Zeta potential [21]), we anticipated that 
AuNP diffusion through membranes is not the domi-
nant penetration mechanism. The BBB, as others bar-
riers in the body, is composed of different tissue types. 
In the following discussion we considered the BBB as a 
uniform organ without addressing specifically different 
components.
An alternative BBB penetration mechanism entails the 
transport of AuNPs through more specific transport sites 
on the BBB. We examined the possibility for existence of 
such mechanism by blocking K+ and Na+ ion channels 
using dofetilide [23] and phenytoin [24], respectively, as 
ion channel blockers, and verapamil as a Ca2+ ion chan-
nel blocker [25]. The blockers were injected abdominally 
1 h after the injection of AuNPs and the concentrations 
of gold in three brain regions (frontal cortex, hippocam-
pus and hypothalamus) showed non-uniformity in the 
gold concentration between the three regions. How-
ever, the fact that in all three regions the gold content 
was markedly reduced compared to the concentrations 
found in the control rats clearly demonstrates that block-
ing the Ca2+, K+ and Na+ ion channels by either blocker 
led to marked reduction of close to 50  % in the total 
Table 2 Comparison of  gold concentrations in  rat urine 
after injection of AuNPs
Time after AuNP  
injection (h)
Gold concentration 
in the urine of four  
different rats  
(mg L−1)
Gold concentration 
in the urine  




16 0.027 Not examined
24 0.013 0.048

























Fig. 2 Change in gold concentrations in different brain regions due 
to exposure to ion channel blockers. Sum of gold concentrations 
measured in different brain regions as observed in the experiments 
with and without injection of the ion channel blockers (verapamil, 
dofetilide and phenytoin). Note that the concentration of the gold 
was normalized to the amount of gold nanoparticles in the solution 
that was injected in the different experiments
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concentration of gold observed in the brain. This suggests 
that blocking ion channels can be used to control AuNPs 
penetration through the BBB.
The injection of ion channel blockers can influence 
AuNPs permeation in the whole body since they are 
expected to affect all ion channels in the body. The influ-
ence of ion channel blockers in internal organs, as the 
kidneys, may lead to reduced amount of AuNPs in the 
blood. Therefore, the reduced concentration of AuNPs 
found in the brain following injection of ion channel 
blockers may reflect a lower concentration of AuNPs in 
the blood. The results described here cannot differentiate 
between these two possibilities and it will be resolved in 
a future publication. Assuming that ion channel blockers 
mainly influence AuNPs permeation through the BBB, it 
can happen in two ways: either by reducing direct pas-
sage of AuNPs through the ion channels or by influencing 
the tight junctions (TJs). Notably the average diameters 
of Ca2+, Na+ and K+ ion channels is in the range 0.9–
1.5 nm [32, 33] matches the average size of a large frac-
tion of the AuNPs used in this study. Thus, one possible 
pathway is penetration of the BBB due to direct trans-
port of small AuNPs through ion channels. However, it 
is known that the penetration through ion channels is 
highly affected and controlled by the affinity of the trans-
ported species to specific binding sites in the ion chan-
nel and not solely by size [34]. For example, although the 
ionic radius of Na+ is smaller than that of K+ its transport 
through K+ ion channels is prevented by the high speci-
ficity of the channel [34]. The specificity of the ion chan-
nels is expected to prevent transport of AuNPs through 
them. It is well established that the use of ion channel 
blockers leads to changes in ionic balance that result in a 
reduced permeability through the TJs [35, 36]. For exam-
ple, variation in the extracellular calcium ion concentra-
tion is a critical component in tight junction regulation 
in models of Ca2+ addition/depletion [37–41]. Moreover, 
there are studies that connect migration through the BBB 
to changes in functionality due to blockage [42]. Hence, it 
is suggested that ion channel blockers can lead to changes 
in ion balance that are expressed in reduction of particle 
transfer through TJs.
Conclusions
To the best of our knowledge, this is the first definitive 
study in which gold nanoparticles, synthesized using 
green chemistry approach, were shown to cross the BBB 
from the blood to various brain regions without the use 
of external fields. AuNP distributions in the hypothala-
mus and hippocampus were found to be nearly uniform 
(see Additional file 2). Injection of Ca2+ or Na+ and K+ 
ion channels blockers leads to 50  % reduction of gold 
concentrations in the brain. This finding suggests that 
either ion channels play a key role in the BBB permeabil-
ity mechanism of small AuNPs or that the ion channel 
blockers influence the penetration of AuNPs through TJs 
due to changes in ion balance. The small diameter of ion 
channels and their high specificity suggests that reduced 
transport through TJs is probably the more important 
cause for the decreased gold concentration in the brain 
when ion channel blockers are used. If trans-membrane 
penetration of the endothelial cells constitutes an impor-
tant route to cross the BBB, the addition of ion channel 
blockers must induce changes in the membrane that 
lead to reduced penetration efficiency of the AuNPs. 
This might also be related to the changes in ion balance 
induced by the ion channel blockers that lead to modifi-
cations in the membrane structure that result in reduced 
AuNPs penetration. This mechanism is supported by 
similar phenomenon described in the literature [35, 36]. 
The reduction in AuNPs concentration in the brain when 
ion channel blockers were injected can also be due to 
decrease in blood concentration of the gold nanoparti-
cles as a result of changes in internal organ functionality 
when the ion channel blockers are present.
The bio-kinetics measurements showed that the tem-
poral concentration profile was practically similar for 
all the body organs and brain regions examined and 
revealed that AuNPs in the rat body has a biological half-
life of approximately 12.9 ± 4.9 h.
This study was aimed to examine the ability of AuNPs 
formed using green chemistry synthesis to penetrate 
through the BBB. Biomedical applications will require the 
encapsulation of drugs or diagnostic agents to the nano-
particles and might add to their size. However, since the 
diameter of the AuNPs used is about 2.5 nm, average size 
organic molecules used in many biomedical applications 
are much smaller and their addition is not expected to 
change significantly the particle size.
These findings suggest that the design of new and effi-
cient drug delivery systems through the BBB could be 
based on the use of small AuNPs. The use of ion chan-
nel blockers allows one to have some control over the 
amount of AuNPs penetrating the BBB. Suitably func-
tionalized AuNPs can also be used as imaging agents, for 
gene delivery or in photodynamic therapy applications as 
shown schematically in Fig.  3. These types of biomedi-
cal applications can be designed to be triggered by light 
at a wavelength suitable for desired interaction with the 
AuNPs that have crossed the BBB.
Methods
AuNPs were produced via the reduction of HAuCl4 by 
several reducing agents, including sodium citrate [43] 
and the extracts of three common plants in Israel, Sal-
via officinalis (Common Sage), Lippia citriodora (Lemon 
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Verbana) and Pelargonium graveolens (Rose Geranium). 
AuNP preparation and characterization using the plant 
extracts has been described in detail [21] and in Addi-
tional file  1. Another group of particles was produced 
by functionalizing particles obtained using sodium cit-
rate as the reducing agent [43] and exposing them to 
11-Mercapto-undecanoic acid (MUDA) or to Perfluoro 
Decanethiol (PFDT) to produce hydrophilic or hydro-
phobic AuNPs, respectively. The size distributions of all 
AuNPs were measured using dynamic light scattering 
(DLS). Normalization of the DLS data according to parti-
cle numbers showed that in all cases the average diameter 
size of the AuNP particles synthesized using Pelargonium 
graveolens was in the range of 1.3  ±  0.3  nm with Zeta 
potential −23.9  ±  2  mV (all error quantities described 
in this study correspond to SD values) [21]. However, the 
concentration of the gold in the injected solution was in 
the range of 60–120 mg L−1 as measured by ICP-MS.
Male Sprague Dawley rats weighing 200–250  g were 
habituated to housing conditions for at least seven days. 
The rats were housed four per cage in a vivarium with 
stable temperature and a reversed 12-h light/dark cycle 
and with unlimited access to food and water. A volume 
of 200 µL of solution containing gold nanoparticles was 
injected into the abdominal cavity of the rats (total of 
12–24  μg Au in each injection depending on the initial 
Au concentration).
The health conditions of the rats that followed the 
injection indicate for normal locomotor activity (with-
out stereotypical behavior, e.g., repeatedly chewing metal 
cage bars), normal eating and drinking, cleaned, normal 
posture, without anxiety and aggression; no vocalisation.
The accumulated amount of gold was determined in 
various regions in the brain (i.e., hippocampus, frontal 
cortex, entire cortex, cerebellum and hypothalamus) and 
in different internal organs (kidneys, liver and spleen). 
Urine samples were collected when it was possible about 
2  h after injection and at the end of the experiments. 
For CSF collection, the animals were anesthetized (ket-
amine and xylazine mixture) and fixed in a stereotactic 
device (for details see Additional file 3). CSF sample vol-
ume ranged from 100–150 µL. Blood samples were col-
lected when the animal was sacrificed.
Perfusion protocol: animals were deeply anesthetized 
(ketamine and xylazine mixture) and perfused transcar-
dially with cold 0.9 % physiological saline followed by 4 % 
paraformaldehyde (Sigma-Aldrich) in 0.1  mol/L phos-
phate buffer (pH 7.4) 220 and 200 mL respectively. Brains 
were quickly removed, post fixed in the same fixative for 
12 h at 4 °C, and were cryo-protected overnight in 30 % 
Fig. 3 Schematic description of light-triggered biomedical applications using functionalized AuNPs that can penetrate the BBB
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sucrose in 0.1 mol/L phosphate buffer at 4 °C. the proce-
dure last 45–60 min.
AuNP bio-kinetics was determined by monitor-
ing the gold concentrations in different body organs 
at different times after AuNP injection. As such, the 
gold concentrations in the different organs were deter-
mined for different rats, where the number of par-
ticipating animals was equal to the number of time 
periods examined. All the animals were injected with 
200 µL of the AuNP solution to their abdominal cavity. 
Animals were sacrificed at predetermined times and 
the gold concentrations in their organs were examined. 
Samples were collected at 2, 6, 16, 24, 36 and 48 h fol-
lowing injection. After the perfusion was performed, 
all the organs were removed and preserved for sub-
sequent analysis of gold concentration. In addition, 
blood and urine samples were also collected for most 
of the examined objects.
Verapamil, dofetilide and phenytoin were used as a 
Ca2+, K+ and Na+ ion channel blockers, respectively, to 
examine their effect on the BBB penetration of AuNPs. 
In these experiments rats were injected with 0.1 mg kg−1 
body weight of Verapamil, or a solution of 1 μg kg−1 body 
weight of dofetilide and 8 mg kg−1 body weight of pheny-
toin 1 h after the injection of the AuNPs. These experi-
ments were terminated by sacrificing the animals 3  h 
following AuNP injection.
Instrumentation: A quadrupole-based Inductively Cou-
pled Plasma-Mass Spectrometer (ICP-MS, ELAN DRC-e, 
Perkin-Elmer Sciex) was used for all elemental analyses. 
The ICP-MS was also coupled to a laser ablation (LA-
ICP-MS) system (CETAC LSX-213, CETAC Technolo-
gies, Inc., Omaha, NE, USA) that enabled the gold spatial 
distribution in slices of rat brain to be characterized and 
imaged. These analyses were carried out at the Geologi-
cal Survey of Israel (GSI), Jerusalem.  For details of the 
parameters used see Additional file 4.
Additional files
Additional file 1. Title of data: Synthesis and characterization of the gold 
nanoparticles (AuNPs). Description of the preparation procedure of the 
AuNPs and Analysis of the matching levels of the different particles to our 
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the present work.
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